ISRCTN12618919已完成不适用
A Multicentre, Phase II, Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response
ational Cancer Institute (NCI) (USA)0 个研究点目标入组 100 人开始时间: 2010年4月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Women, aged = 18
- •2. Diagnosis of invasive breast cancer
- •3. Tumor more than 3 cm and palpable
- •4. Multiple masses are allowed provided at least 1 mass is more than 3 cm
- •5. Clinically positive axillary or supraclavicular lymph nodes allowed
- •6. Fine needle aspiration or core needle biopsy positive for invasive breast cancer AND/OR fine needle aspiration of lymph nodes positive
- •7. Estrogen receptor (ER)-positive OR ER-negative
- •8. ER2/neu-positive OR negative
- •9. Premenopausal or postmenopausal
- •10. Performance status: Karnofsky 60-100%
- •11. Granulocyte count more than 1,000/mm^3
- •12. Platelet count more than 100,000/cmm
- •13. Bilirubin more than 2 times upper limit of normal (ULN)
- •14. Serum glutamic oxaloacetic transaminase (SGOT) more than 2 times ULN
- •15. Left Ventricular Ejection Fraction (LVEF) not less than 50%
排除标准
- •1. Inflammatory breast cancer
- •2. Distant metastases
- •3. Congestive heart failure or other significant cardiovascular disease
- •4. Pregnancy or nursing
- •5. Severe medical or psychiatric condition that would preclude study compliance
- •6. HIV positivity
- •7. Patients with other prior or concurrent malignancies if they have received prior chemotherapy or are not cured from the prior malignancy
研究者
相似试验
进行中（未招募）
1 期
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Gonorrhea in AdultsEUCTR2015-005120-26-GBGlaxoSmithKline Research and Development Limited106
进行中（未招募）
不适用
A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid ®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relapse after two lines of treatment(RV-405 LAL) - RV-405 LATreatment for B-cell Acute lymphoblastic leukemia in relapse.EUCTR2009-009372-13-FRInstitut de Cancérologie de la Loire
未知
2 期
A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safetyand Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusJPRN-jRCT2080221785AstraZeneca
进行中（未招募）
1 期
/ACentronuclear myopathy (CNM), in subjects 2 to 17 years of age (all ages inclusive)caused by mutations in the myotubularin1 (MTM1) or dynamin 2 (DNM2) geneMedDRA version: 20.0Level: HLTClassification code 10028640Term: MyopathiesSystem Organ Class: 100000004859EUCTR2020-004608-32-DEDynacure9
进行中（未招募）
1 期
A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessingthe Safety and Efficacy of PD 0348292 in the Prevention of Venous ThromboembolicEvents (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement - N/APrevention of Venous Thromboembolic EventsMedDRA version: 8.0Level: HLGTClassification code 10014523EUCTR2005-005179-14-DKPfizer Limited1,255